| Year |
Citation |
Score |
| 2023 |
Bremner JD, Gazi AH, Lambert TP, Nawar A, Harrison AB, Welsh JW, Vaccarino V, Walton KM, Jaquemet N, Mermin-Bunnell K, Mesfin H, Gray TA, Ross K, Saks G, Tomic N, ... ... Dunn KE, et al. Noninvasive Vagal Nerve Stimulation for Opioid Use Disorder. Annals of Depression and Anxiety. 10. PMID 38074313 |
0.37 |
|
| 2023 |
Durgin CJ, Huhn AS, Bergeria CL, Finan PH, Campbell CM, Antoine DG, Dunn KE. Within subject, double blind, examination of opioid sensitivity in participant-reported, observed, physiologic, and analgesic outcomes. Drug and Alcohol Dependence Reports. 8: 100188. PMID 37731966 DOI: 10.1016/j.dadr.2023.100188 |
0.416 |
|
| 2023 |
Ware OD, Dunn KE. Clinically meaningful individual differences in opioid withdrawal expression. Experimental and Clinical Psychopharmacology. PMID 37166910 DOI: 10.1037/pha0000654 |
0.359 |
|
| 2023 |
Dunn KE, Bird HE, Bergeria CL, Ware OD, Strain EC, Huhn AS. Operational definition of precipitated opioid withdrawal. Frontiers in Psychiatry. 14: 1141980. PMID 37151972 DOI: 10.3389/fpsyt.2023.1141980 |
0.356 |
|
| 2023 |
Dunn KE. Iteration is not solving the opioid crisis, it's time for transformation. The American Journal of Drug and Alcohol Abuse. 1-8. PMID 36920881 DOI: 10.1080/00952990.2023.2170807 |
0.341 |
|
| 2023 |
Ware OD, Sweeney MM, Cunningham C, Umbricht A, Stitzer M, Dunn KE. Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder: A Randomized Clinical Trial. Jama Network Open. 6: e232278. PMID 36920397 DOI: 10.1001/jamanetworkopen.2023.2278 |
0.387 |
|
| 2022 |
Kiluk BD, Kleykamp BA, Comer SD, Griffiths RR, Huhn AS, Johnson MW, Kampman KM, Pravetoni M, Preston KL, Vandrey R, Bergeria CL, Bogenschutz MP, Brown RT, Dunn KE, Dworkin RH, et al. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review. Jama Psychiatry. PMID 36449315 DOI: 10.1001/jamapsychiatry.2022.4020 |
0.532 |
|
| 2022 |
Ware OD, Ellis JD, Dunn KE, Hobelmann JG, Finan P, Huhn AS. The association of chronic pain and opioid withdrawal in men and women with opioid use disorder. Drug and Alcohol Dependence. 240: 109631. PMID 36126611 DOI: 10.1016/j.drugalcdep.2022.109631 |
0.342 |
|
| 2022 |
Dunn KE. Advocating for a Thoughtful Expansion of Safer Supply to Realize Bold Impact on Opioid Overdose. Journal of Studies On Alcohol and Drugs. 83: 621-622. PMID 35838441 |
0.358 |
|
| 2022 |
Mun CJ, Nordeck C, Goodell EMA, Vandrey R, Zipunnikov V, Dunn KE, Finan PH, Thrul J. Real-time monitoring of cannabis and prescription opioid co-use patterns, analgesic effectiveness, and the opioid-sparing effect of cannabis in individuals with chronic pain. The Journal of Pain. PMID 35817255 DOI: 10.1016/j.jpain.2022.06.009 |
0.359 |
|
| 2022 |
Huhn AS, Finan PH, Gamaldo CE, Hammond AS, Umbricht A, Bergeria CL, Strain EC, Dunn KE. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Science Translational Medicine. 14: eabn8238. PMID 35731889 DOI: 10.1126/scitranslmed.abn8238 |
0.369 |
|
| 2022 |
Strickland JC, Gipson CD, Dunn KE. Dopamine Supersensitivity: A Novel Hypothesis of Opioid-Induced Neurobiological Mechanisms Underlying Opioid-Stimulant Co-use and Opioid Relapse. Frontiers in Psychiatry. 13: 835816. PMID 35492733 DOI: 10.3389/fpsyt.2022.835816 |
0.413 |
|
| 2022 |
Sweeney MM, Prichett L, Fingerhood MI, Antoine D, Umbricht A, Dunn KE, Buresh ME. Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting. The American Journal On Addictions. PMID 35385169 DOI: 10.1111/ajad.13268 |
0.333 |
|
| 2022 |
Bergeria CL, Tan H, Antoine D, Weerts EM, Huhn AS, Hobelmann JG, Dunn KE. A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal. Experimental and Clinical Psychopharmacology. PMID 35266779 DOI: 10.1037/pha0000550 |
0.378 |
|
| 2021 |
Varshneya NB, Thakrar AP, Hobelmann JG, Dunn KE, Huhn AS. Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl. Journal of Addiction Medicine. PMID 34816821 DOI: 10.1097/ADM.0000000000000922 |
0.367 |
|
| 2021 |
Smith KE, Dunn KE, Grundmann O, Garcia-Romeu A, Rogers JM, Swogger MT, Epstein DH. Social, psychological, and substance use characteristics of U.S. adults who use kratom: Initial findings from an online, crowdsourced study. Experimental and Clinical Psychopharmacology. PMID 34735202 DOI: 10.1037/pha0000518 |
0.358 |
|
| 2021 |
Dolan SB, Johnson MW, Dunn KE, Huhn AS. The discounting of death: Probability discounting of heroin use by fatal overdose likelihood and drug purity. Experimental and Clinical Psychopharmacology. 29: 219-228. PMID 34264734 DOI: 10.1037/pha0000486 |
0.326 |
|
| 2021 |
Oswald LM, Dunn KE, Seminowicz DA, Storr CL. Early Life Stress and Risks for Opioid Misuse: Review of Data Supporting Neurobiological Underpinnings. Journal of Personalized Medicine. 11. PMID 33921642 DOI: 10.3390/jpm11040315 |
0.377 |
|
| 2021 |
Dunn KE, Bergeria CL, Huhn AS, Speed TJ, Mun CJ, Vandrey R, Campbell CM. Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 33879842 DOI: 10.1038/s41386-021-01007-4 |
0.325 |
|
| 2021 |
Nayak SM, Huhn AS, Bergeria CL, Strain EC, Dunn KE. Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder. Drug and Alcohol Dependence. 221: 108649. PMID 33640679 DOI: 10.1016/j.drugalcdep.2021.108649 |
0.302 |
|
| 2021 |
Dunn KE, Brooner RK, Stoller KB. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic. Journal of Substance Abuse Treatment. 121: 108197. PMID 33357606 DOI: 10.1016/j.jsat.2020.108197 |
0.357 |
|
| 2020 |
Bergeria CL, Strickland JC, Huhn AS, Strain EC, Dunn KE. A preliminary examination of the multiple dimensions of opioid craving. Drug and Alcohol Dependence. 219: 108473. PMID 33429294 DOI: 10.1016/j.drugalcdep.2020.108473 |
0.422 |
|
| 2020 |
Strickland JC, Huhn AS, Bergeria CL, Strain EC, Dunn KE. Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D. Journal of Addiction Medicine. PMID 33156180 DOI: 10.1097/ADM.0000000000000765 |
0.316 |
|
| 2020 |
Dunn K, Bergeria C, Huhn AS, Strain EC. Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome. Drug and Alcohol Dependence. 215: 108212. PMID 32781310 DOI: 10.1016/J.Drugalcdep.2020.108212 |
0.415 |
|
| 2020 |
Antoine D, Huhn AS, Strain EC, Turner G, Jardot J, Hammond AS, Dunn KE. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone. The American Journal On Addictions. PMID 32572978 DOI: 10.1111/Ajad.13069 |
0.382 |
|
| 2020 |
Bergeria CL, Huhn AS, Dunn KE. The impact of naturalistic cannabis use on self-reported opioid withdrawal. Journal of Substance Abuse Treatment. 113: 108005. PMID 32359667 DOI: 10.1016/J.Jsat.2020.108005 |
0.511 |
|
| 2020 |
Gipson CD, Dunn KE, Bull A, Ulangkaya H, Hossain A. Establishing preclinical withdrawal syndrome symptomatology following heroin self-administration in male and female rats. Experimental and Clinical Psychopharmacology. PMID 32297787 DOI: 10.1037/Pha0000375 |
0.42 |
|
| 2020 |
Bergeria CL, Dolan SB, Johnson MW, Campbell CM, Dunn KE. Evaluating the co-use of opioids and cannabis for pain among current users using hypothetical purchase tasks. Journal of Psychopharmacology (Oxford, England). 269881120914211. PMID 32267192 DOI: 10.1177/0269881120914211 |
0.471 |
|
| 2020 |
Huhn AS, Hobelmann JG, Strickland JC, Oyler GA, Bergeria CL, Umbricht A, Dunn KE. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States. Jama Network Open. 3: e1920843. PMID 32031650 DOI: 10.1001/jamanetworkopen.2019.20843 |
0.345 |
|
| 2020 |
Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence. 107849. PMID 32029298 DOI: 10.1016/J.Drugalcdep.2020.107849 |
0.586 |
|
| 2019 |
Dunn KE, Huhn AS, Strain EC. Differential adoption of opioid agonist treatments in detoxification and outpatient settings. Journal of Substance Abuse Treatment. 107: 24-28. PMID 31757261 DOI: 10.1016/J.Jsat.2019.10.002 |
0.449 |
|
| 2019 |
Dunn KE, Barrett FS, Brands B, Marsh DC, Bigelow GE. Individual differences in human opioid abuse potential as observed in a human laboratory study. Drug and Alcohol Dependence. 205: 107688. PMID 31710994 DOI: 10.1016/J.Drugalcdep.2019.107688 |
0.496 |
|
| 2019 |
Huhn AS, Brooner RK, Sweeney MM, Yip SW, Ayaz H, Dunn KE. Increased neural activity in the right dorsolateral prefrontal cortex during a risky decision-making task is associated with cocaine use in methadone-maintained patients. Drug and Alcohol Dependence. 205: 107650. PMID 31669801 DOI: 10.1016/J.Drugalcdep.2019.107650 |
0.374 |
|
| 2019 |
Dunn KE, Bergeria CL, Huhn AS, Strain EC. A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans. Frontiers in Psychiatry. 10: 704. PMID 31616329 DOI: 10.3389/Fpsyt.2019.00704 |
0.533 |
|
| 2019 |
Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM. Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence. The Journal of Pharmacology and Experimental Therapeutics. PMID 31391211 DOI: 10.1124/Jpet.119.258004 |
0.521 |
|
| 2019 |
Hammond AS, Dunn KE, Strain EC. Drug Legalization and Decriminalization Beliefs Among Substance-using and Nonusing Individuals. Journal of Addiction Medicine. PMID 31385846 DOI: 10.1097/Adm.0000000000000542 |
0.405 |
|
| 2019 |
Chilcoat HD, Amick HR, Sherwood MR, Dunn KE. Buprenorphine in the United States: Motives for abuse, misuse, and diversion. Journal of Substance Abuse Treatment. 104: 148-157. PMID 31370979 DOI: 10.1016/J.Jsat.2019.07.005 |
0.515 |
|
| 2019 |
Bergeria CL, Huhn AS, Tompkins DA, Bigelow GE, Strain EC, Dunn KE. The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal. Drug and Alcohol Dependence. 202: 111-114. PMID 31336328 DOI: 10.1016/J.Drugalcdep.2019.05.010 |
0.503 |
|
| 2019 |
Huhn AS, Berry MS, Dunn KE. Review: Sex-Based Differences in Treatment Outcomes for Persons With Opioid Use Disorder. The American Journal On Addictions. PMID 31131505 DOI: 10.1111/Ajad.12921 |
0.429 |
|
| 2019 |
Bergeria CL, Huhn AS, Dunn KE. Randomized comparison of two web-based interventions on immediate and 30-day opioid overdose knowledge in three unique risk groups. Preventive Medicine. PMID 31078564 DOI: 10.1016/J.Ypmed.2019.05.006 |
0.482 |
|
| 2019 |
Huhn AS, Tompkins DA, Campbell CM, Dunn KE. Individuals with Chronic Pain Who Misuse Prescription Opioids Report Sex-Based Differences in Pain and Opioid Withdrawal. Pain Medicine (Malden, Mass.). PMID 30690594 DOI: 10.1093/Pm/Pny295 |
0.399 |
|
| 2019 |
Hay KR, Huhn AS, Tompkins DA, Dunn KE. Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use. Journal of Addiction Medicine. PMID 30633045 DOI: 10.1097/Adm.0000000000000498 |
0.514 |
|
| 2018 |
Dunn KE. Promoting a comprehensive understanding of the opioid epidemic. International Review of Psychiatry (Abingdon, England). 30: 89-90. PMID 31282809 DOI: 10.1080/09540261.2018.1530168 |
0.482 |
|
| 2018 |
Huhn AS, Berry MS, Dunn KE. Systematic review of sex-based differences in opioid-based effects. International Review of Psychiatry (Abingdon, England). 1-10. PMID 30522374 DOI: 10.1080/09540261.2018.1514295 |
0.492 |
|
| 2018 |
Huhn AS, Strain EC, Tompkins DA, Dunn KE. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. Drug and Alcohol Dependence. 193: 142-147. PMID 30384321 DOI: 10.1016/J.Drugalcdep.2018.10.002 |
0.452 |
|
| 2018 |
Huhn AS, Sweeney MM, Brooner K, Kidorf MS, Tompkins DA, Ayaz H, Dunn KE. Prefrontal cortex Response to Drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 30375498 DOI: 10.1038/S41386-018-0252-0 |
0.473 |
|
| 2018 |
Dunn KE, Weerts EM, Huhn AS, Schroeder JR, Tompkins DA, Bigelow GE, Strain EC. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. Addiction Biology. PMID 30295400 DOI: 10.1111/Adb.12680 |
0.521 |
|
| 2018 |
Dunn KE, Barrett FS, Bigelow GE. Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management. Addictive Behaviors. PMID 29625751 DOI: 10.1016/J.Addbeh.2018.03.011 |
0.467 |
|
| 2018 |
Huhn AS, Garcia-Romeu AP, Dunn KE. Opioid Overdose Education for Individuals Prescribed Opioids for Pain Management: Randomized Comparison of Two Computer-Based Interventions. Frontiers in Psychiatry. 9: 34. PMID 29483884 DOI: 10.3389/Fpsyt.2018.00034 |
0.529 |
|
| 2018 |
Huhn A, Sweeney M, Kidorf M, Tompkins D, Brooner R, Ayaz H, Dunn K. Prefrontal Cortex Response to Drug Cues, Craving, and Current Depressive Symptoms are Associated with Relapse to Opioids in Methadone-maintained Patients Frontiers in Human Neuroscience. 12. DOI: 10.3389/Conf.Fnhum.2018.227.00128 |
0.367 |
|
| 2017 |
Dunn KE, Tompkins DA, Strain EC. Tramadol Extended-Release and Opioid Withdrawal Management-Legal Implications-Reply. Jama Psychiatry. PMID 29282473 DOI: 10.1001/Jamapsychiatry.2017.3827 |
0.411 |
|
| 2017 |
Dunn KE, Brands B, Marsh DC, Bigelow GE. Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study. Psychopharmacology. PMID 29270641 DOI: 10.1007/S00213-017-4814-3 |
0.458 |
|
| 2017 |
Dunn KE, Brands B, Marsh DC, Bigelow GE. Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study. Psychopharmacology. PMID 29270641 DOI: 10.1007/s00213-017-4814-3 |
0.354 |
|
| 2017 |
Dunn KE, Brands B, Marsh DC, Bigelow GE. Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study. Psychopharmacology. PMID 29270641 DOI: 10.1007/s00213-017-4814-3 |
0.354 |
|
| 2017 |
Huhn AS, Tompkins DA, Dunn KE. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. Drug and Alcohol Dependence. 180: 279-285. PMID 28942031 DOI: 10.1016/J.Drugalcdep.2017.08.019 |
0.447 |
|
| 2017 |
Finan PH, Remeniuk B, Dunn KE. The risk for problematic opioid use in chronic pain: What can we learn from studies of pain and reward? Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28778406 DOI: 10.1016/J.Pnpbp.2017.07.029 |
0.414 |
|
| 2017 |
Dunn KE, Finan PH, Andrew Tompkins D, Strain EC. Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients. Addictive Behaviors. 76: 8-14. PMID 28735039 DOI: 10.1016/J.Addbeh.2017.07.016 |
0.411 |
|
| 2017 |
Dunn KE, Tompkins DA, Bigelow GE, Strain EC. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial. Jama Psychiatry. PMID 28700791 DOI: 10.1001/Jamapsychiatry.2017.1838 |
0.496 |
|
| 2017 |
Huhn AS, Dunn KE. Why aren't physicians prescribing more buprenorphine? Journal of Substance Abuse Treatment. 78: 1-7. PMID 28554597 DOI: 10.1016/J.Jsat.2017.04.005 |
0.434 |
|
| 2017 |
Dunn KE, Yepez-Laubach C, Nuzzo PA, Fingerhood M, Kelly A, Berman S, Bigelow GE. Randomized controlled trial of a computerized opioid overdose education intervention. Drug and Alcohol Dependence. 173: S39-S47. PMID 28363318 DOI: 10.1016/J.Drugalcdep.2016.12.003 |
0.515 |
|
| 2017 |
Dunn KE, Tompkins D, Bigelow G, Strain EC. Randomized controlled evaluation of tramadol for opioid detoxification Drug and Alcohol Dependence. 171: e57. DOI: 10.1016/J.Drugalcdep.2016.08.168 |
0.451 |
|
| 2016 |
Jarvis BP, Holtyn AF, DeFulio A, Dunn KE, Everly JJ, Leoutsakos JS, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults. Addiction (Abingdon, England). PMID 27936293 DOI: 10.1111/Add.13724 |
0.732 |
|
| 2016 |
Dunn KE, Barrett FS, Yepez-Laubach C, Meyer AC, Hruska BJ, Petrush K, Berman S, Sigmon SC, Fingerhood M, Bigelow GE. Opioid Overdose Experience, Risk Behaviors, and Knowledge in Drug Users from a Rural versus an Urban Setting. Journal of Substance Abuse Treatment. 71: 1-7. PMID 27672239 DOI: 10.1016/J.Jsat.2016.08.006 |
0.673 |
|
| 2016 |
Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, Strain EC, Dunn KE, Kampman K, Mahoney E, Ciraulo DA, Sickles-Colaneri L, Ait-Daoud N, Johnson BA, Ransom J, et al. A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 27658483 DOI: 10.1038/Npp.2016.214 |
0.342 |
|
| 2016 |
Dunn KE, Barrett FS, Fingerhood M, Bigelow GE. Opioid Overdose History, Risk Behaviors, and Knowledge in Patients Taking Prescribed Opioids for Chronic Pain. Pain Medicine (Malden, Mass.). PMID 27651504 DOI: 10.1093/Pm/Pnw228 |
0.47 |
|
| 2016 |
Dunn KE, Barrett FS, Herrmann ES, Plebani JG, Sigmon SC, Johnson MW. Behavioral risk assessment for infectious diseases (BRAID): Self-report instrument to assess injection and noninjection risk behaviors in substance users. Drug and Alcohol Dependence. 168: 69-75. PMID 27615403 DOI: 10.1016/J.Drugalcdep.2016.07.032 |
0.551 |
|
| 2016 |
Dunn KE, Harrison JA, Leoutsakos JM, Han D, Strain EC. Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence. Alcohol and Alcoholism (Oxford, Oxfordshire). PMID 27567268 DOI: 10.1093/Alcalc/Agw059 |
0.341 |
|
| 2016 |
Dunn KE, Barrett FS, Yepez-Laubach C, Meyer AC, Hruska BJ, Sigmon SC, Fingerhood M, Bigelow GE. Brief Opioid Overdose Knowledge (BOOK): A Questionnaire to Assess Overdose Knowledge in Individuals Who Use Illicit or Prescribed Opioids. Journal of Addiction Medicine. PMID 27504923 DOI: 10.1097/Adm.0000000000000235 |
0.679 |
|
| 2016 |
Dunn KE, Barrett FS, Yepez-Laubach C, Meyer AC, Hruska BJ, Petrush K, Berman S, Sigmon SC, Fingerhood M, Bigelow GE. Opioid overdose experience, risk behaviors, and knowledge in drug users from a rural versus an urban setting Journal of Substance Abuse Treatment. 71: 1-7. DOI: 10.1016/j.jsat.2016.08.006 |
0.655 |
|
| 2015 |
Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, Litten RZ, McCann DJ, Montoya ID, Preston KL, Skolnick P, Weisner C, Woody G, Chandler R, Detke MJ, ... Dunn K, et al. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug and Alcohol Dependence. PMID 26652899 DOI: 10.1016/J.Drugalcdep.2015.11.004 |
0.535 |
|
| 2015 |
Dunn KE, Finan PH, Tompkins DA, Fingerhood M, Strain EC. Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients. Drug and Alcohol Dependence. PMID 26518253 DOI: 10.1016/J.Drugalcdep.2015.10.018 |
0.406 |
|
| 2015 |
Dunn K, Marcus T, Kim C, Schroeder JR, Vandrey R, Umbricht A. Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-induced Smoking Cessation. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. PMID 26476459 DOI: 10.1093/Ntr/Ntv236 |
0.36 |
|
| 2015 |
Dunn KE, Saulsgiver KA, Miller ME, Nuzzo PA, Sigmon SC. Characterizing opioid withdrawal during double-blind buprenorphine detoxification. Drug and Alcohol Dependence. 151: 47-55. PMID 25823907 DOI: 10.1016/J.Drugalcdep.2015.02.033 |
0.687 |
|
| 2015 |
Dunn K, DeFulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes. Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors. 29: 270-6. PMID 25134047 DOI: 10.1037/Adb0000010 |
0.784 |
|
| 2014 |
Patrick ME, Dunn KE, Badger GJ, Heil SH, Higgins ST, Sigmon SC. Spontaneous reductions in smoking during double-blind buprenorphine detoxification. Addictive Behaviors. 39: 1353-6. PMID 24845165 DOI: 10.1016/J.Addbeh.2014.04.023 |
0.717 |
|
| 2014 |
Dunn KE, Brooner RK, Clark MR. Severity and interference of chronic pain in methadone-maintained outpatients. Pain Medicine (Malden, Mass.). 15: 1540-8. PMID 24703517 DOI: 10.1111/Pme.12430 |
0.362 |
|
| 2014 |
Dunn KE, Fingerhood M, Wong CJ, Svikis DS, Nuzzo P, Silverman K. Employment-based abstinence reinforcement following inpatient detoxification in HIV-positive opioid and/or cocaine-dependent patients. Experimental and Clinical Psychopharmacology. 22: 75-85. PMID 24490712 DOI: 10.1037/A0034863 |
0.687 |
|
| 2014 |
McClure EA, Acquavita SP, Dunn KE, Stoller KB, Stitzer ML. Characterizing smoking, cessation services, and quit interest across outpatient substance abuse treatment modalities. Journal of Substance Abuse Treatment. 46: 194-201. PMID 23988192 DOI: 10.1016/J.Jsat.2013.07.009 |
0.415 |
|
| 2013 |
Sigmon SC, Dunn KE, Saulsgiver K, Patrick ME, Badger GJ, Heil SH, Brooklyn JR, Higgins ST. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. Jama Psychiatry. 70: 1347-54. PMID 24153411 DOI: 10.1001/Jamapsychiatry.2013.2216 |
0.728 |
|
| 2013 |
Dunn KE, Saulsgiver KA, Patrick ME, Heil SH, Higgins ST, Sigmon SC. Characterizing and improving HIV and hepatitis knowledge among primary prescription opioid abusers. Drug and Alcohol Dependence. 133: 625-32. PMID 24051063 DOI: 10.1016/J.Drugalcdep.2013.08.007 |
0.667 |
|
| 2013 |
Dunn KE, Strain EC. Pretreatment alcohol drinking goals are associated with treatment outcomes Alcoholism: Clinical and Experimental Research. 37: 1745-1752. PMID 23800222 DOI: 10.1111/Acer.12137 |
0.326 |
|
| 2013 |
Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. Journal of Addiction Medicine. 7: 277-86. PMID 23728065 DOI: 10.1097/Adm.0B013E31829623F4 |
0.33 |
|
| 2013 |
Dunn KE, Defulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Experimental and Clinical Psychopharmacology. 21: 74-83. PMID 23205722 DOI: 10.1037/A0030743 |
0.758 |
|
| 2013 |
Herrmann ES, Heil SH, Sigmon SC, Dunn KE, Washio Y, Higgins ST. Characterizing and improving HIV/AIDS knowledge among cocaine-dependent outpatients using modified materials. Drug and Alcohol Dependence. 127: 220-5. PMID 22889696 DOI: 10.1016/J.Drugalcdep.2012.07.006 |
0.674 |
|
| 2012 |
Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids) Drug and Alcohol Dependence. 120: 238-241. PMID 21835562 DOI: 10.1016/J.Drugalcdep.2011.07.011 |
0.367 |
|
| 2011 |
Dunn KE, Sigmon SC, Strain EC, Heil SH, Higgins ST. The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. Drug and Alcohol Dependence. 119: 1-9. PMID 21741781 DOI: 10.1016/J.Drugalcdep.2011.05.033 |
0.697 |
|
| 2011 |
Dunn KE, Saulsgiver KA, Sigmon SC. Contingency Management for Behavior Change: Applications to Promote Brief Smoking Cessation Among Opioid-Maintained Patients Experimental and Clinical Psychopharmacology. 19: 20-30. PMID 21341920 DOI: 10.1037/A0022039 |
0.658 |
|
| 2010 |
Dunn KE, Sigmon SC, Reimann EF, Badger GJ, Heil SH, Higgins ST. A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients. Experimental and Clinical Psychopharmacology. 18: 37-50. PMID 20158293 DOI: 10.1037/A0018649 |
0.701 |
|
| 2009 |
Dunn KE, Sigmon SC, Reimann E, Heil SH, Higgins ST. Effects of Smoking Cessation on Illicit Drug Use among Opioid Maintenance Patients: A Pilot Study. Journal of Drug Issues. 39: 313-328. PMID 20401340 DOI: 10.1177/002204260903900205 |
0.734 |
|
| 2009 |
Sigmon SC, Dunn KE, Badger GJ, Heil SH, Higgins ST. Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study. Addictive Behaviors. 34: 304-11. PMID 19081679 DOI: 10.1016/J.Addbeh.2008.11.017 |
0.74 |
|
| 2009 |
Dunn KE, Sigmon SC, Reimann E, Heil SH, Higgins ST. Effects of smoking cessation on illicit drug use among opioid maintenance patients: A pilot study Journal of Drug Issues. 39: 313-328. |
0.708 |
|
| 2008 |
Dunn KE, Sigmon SC, Thomas CS, Heil SH, Higgins ST. Voucher-based contingent reinforcement of smoking abstinence among methadone-maintained patients: a pilot study. Journal of Applied Behavior Analysis. 41: 527-38. PMID 19192857 DOI: 10.1901/Jaba.2008.41-527 |
0.676 |
|
| 2008 |
Dunn KE, Sigmon SC, McGee MR, Heil SH, Higgins ST. Evaluation of ongoing oxycodone abuse among methadone-maintained patients. Journal of Substance Abuse Treatment. 35: 451-6. PMID 18295434 DOI: 10.1016/J.Jsat.2007.12.006 |
0.738 |
|
| Show low-probability matches. |